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Identity 
Other names: bHLHb11, FCHL, FCHL1, 
HYPLIP1, MLTF, MLTF1, UEF 
HGNC (Hugo): USF1 
Location: 1q23.3 
Local order: 
From centromere to telomere: 
F11R (F11 receptor) (on reverse strand), TSTD1 
(thiosulfate sulfurtransferase (rhodanese)-like domain 
containing 1) (on reverse strand), USF1 (upstream 
transcription factor 1) (on reverse strand), ARHGAP30 
(Rho GTPase activating protein 30) (on reverse strand), 
PVRL4 (poliovirus receptor-related 4) (on reverse 
strand), KLHDC9 (kelch domain containing 9) (on plus 
strand), PFDN2 (prefoldin subunit 2) (on reverse 
strand). 
Note 
USF1 is a bHLH-ZIP transcription factor which forms 
homo-dimers or heterodimers with USF2, a highly 
homologous bHLH-ZIP transcription factor. USF1 and 
USF2 homo- and heterodimers are similarly active in 
affecting transcription of most target genes. USF2 
homodimers may have additional effects. 
DNA/RNA 
Description 
The human USF1 gene on chromosome 1q23 spans 
6.73 kb and 11 exons. 
Transcription 
The mRNA is about 1870 nt. Translation is from a start 
codon in exon 2 and ends at a stop codon in exon 11, 
and results in a 310 amino acid protein product. In a 
splice variant, an alternative donor splice site within 
exon 4 is used; translation from this variant mRNA is 
from an in-frame start codon in exon 5, and results in a 
251 amino acid protein product (Saito et al., 2003). 
 
 
Human USF1 gene diagram. Exons 1 through 11 are depicted by boxes, the open reading frames of the USF1 protein and the splice 
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Functional domains of the USF1 protein. The A1 domain is important for E-box dependent transactivation, the USR (USF-specific region) 
and A2 domains are important for E-box and initiator element (Inr)-dependent transactivation (Roy et al., 1997). Post-translational 
modifications that affect USF1 function are indicated. The protein product of the splice variant lacks the first 59 amino acids, dimerizes 




USF1 belongs to the bHLH-Zip class of transcription 
factors. The bHLH-ZIP domains are important for 
DNA binding and dimerization. USF homo- and 
heterodimers activate transcription of target genes 
through binding either at distal E-box elements or at 
pyrimidine-rich Inr elements in the core promoter (Roy 
et al., 1997). Whole genome ChIP-chip analysis in 
human hepatoma HepG2 cells showed that USF1 and 
USF2 bind predominantly to CACGTGAC elements 
(Rada-Iglesias et al., 2008). In addition, USF2 but not 
USF1 binds to pyrimidine rich elements, suggesting 
that transactivation through Inr elements is mainly 
through USF2. Transactivation activity critically 
depends on post-translational modification of USF1. 
DNA binding to the E-box element is increased by 
phosphorylation of USF1 by the cdk1, p38 stress-
activated kinase, protein kinase A and protein kinase C 
pathway (Corre and Galibert, 2005), whereas 
phosphorylation through the PI3Kinase pathway leads 
to loss of DNA binding activity to the ApoAV 
promoter (Nowak et al., 2005). Cellular stress stimuli 
such as DNA damage, oxidative stress and heavy metal 
exposure, induce p38-mediated phosphorylation at T
153
 
and increased USF1 transactivation activity. Upon 
increased and/or prolonged stress exposure, USF1 
phosphorylated at T
153
 becomes acetylated at K
199
 with 
concomitant loss of transactivation activity (Corre et 
al., 2009). In fasting-refeeding cycles, insulin increases 
the transactivation activity of USF1 via DNA-PK 
mediated phosphorylation of residue S
262
 and 
subsequent acetylation at K
237
 (Wong et al., 2009). 
Expression 
The USF1 gene is ubiquitously expressed (Sirito et al., 
1994). 
Localisation 
The USF1 protein is located in the nucleus. 
Function 
USF1 has been shown to play an important role in 
transcriptional regulation of a huge number of 
seemingly unrelated genes (Corre and Galibert, 2005; 
Rada-Iglesias et al., 2008), consistent with the abundant 
distribution of E-box like elements in the genome. 
Whole-genome ChIP analysis in HepG2 cells identified 
2518 USF1 binding sites in chromatin context, of 
which 41 % were located within 1 kb of a transcription 
start site (Rade-Iglesias et al., 2008). USF1 binding 
signals strongly correlate with target gene expression 
levels, suggesting that USF1 plays an important role in 
transcription activation. USF1 physically interacts with 
histone modifying enzymes, transcription preinitiation 
complex factors, coactivator and corepressor proteins 
(Corre and Galibert, 2005; Huang et al., 2007; Corre et 
al., 2009; Wong et al., 2009). In addition, USF1 
interacts with other transcription factors to achieve 
cooperative transcriptional activation of individual 
genes (Corre and Galibert, 2005). USF1 also plays a 
crucial role in chromatin barrier insulator function, in 
which euchromatin regions are protected from 
heterochromatin-induced gene silencing (Huang et al., 
2007). USFs recruit histone modifying enzymes to the 
insulator element, which modify the adjacent 
nucleosomes thereby maintaining chromatin in an open 
state and preventing heterochromatin spread. Similarly, 
USFs main function at enhancer elements may be to 
render the adjacent region accessible for binding of 
other, bona fide transcription factors, by the 
recruitment of histone modifying enzymes (Huang et 
al., 2007).  
Tumor suppression: Several lines of evidence support 
the hypothesis that USF1 may act as a tumor 
suppressor. First, USF1 is involved in the 
transcriptional activation of several tumor suppressor 
genes (e.g. p53, APC, BRCA2, PTEN, SSeCKS) 
(Corre and Galibert, 2005; Pezzolesi et al., 2007; Bu 
and Gelman, 2007), and represses expression of human 
telomerase reverse transcriptase TERT (McMurray and 
McCance, 2003; Chang et al., 2005). Second, USF1 is 
involved in cell cycle control (Cogswell et al., 1995) 
and overexpression of USF1 slows G2/M transition in 
thyrocytes and thyroid carcinoma cells (Jung et al., 
2007). Third, USF1 overexpression leads to a strong 
reduction in cell proliferation in Ha-Ras/c-Myc 
transformed fibroblasts (Luo and Sawadogo, 1996). 
Fourth, USF1 transactivation activity is completely lost 
in three out of six transformed breast cell lines (Ismail 
et al., 1999). Fifth, USF1 antagonizes some activities of 
the oncoprotein c-Myc, possibly by competing for the 
same DNA binding sites (Luo and Sawadogo, 1996; 
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McMurray and McCance, 2003). Definitive proof that 
USF1 is a tumor suppressor protein, e.g. showing that 
USF1 knockdown increases cell proliferation and 
tumor formation, however, is still missing. This proof 
may be hard to gain, as USF2 may compensate for 
USF1 loss, and USF2 appears to have a broader 
antiproliferative function than USF1 (Luo and 
Sadawogo, 1996; Sirito et al., 1998; Vallet et al., 1998). 
Homology 
The USF1 gene is widely conserved with orthologs 




Of the 121 SNPs in the USF1 gene collected in the 
dbSNP database, only the rs4126997 T>C 
polymorphism causes a non-synchronous mutation 
(V
15
A missense), but data on allele frequency or 
functional effects are not available. The two SNPs that 
are shown to be functional, rs2073658 A>G in intron 7 
(heterozygosity 0.296) and rs3737787 C>T in the 3'-
UTR (heterozygosity 0.309), are in almost complete 
linkage disequilibrium. The minor allele is 
accompanied by normal USF1 expression in human 
muscle and fat tissue but loss of insulin-induced 
upregulation of USF1 mRNA and known USF1 target 
genes (Naukkarinen et al., 2005; Naukkarinen et al., 
2009), as well as reduced insulin-mediated anti-




Given the suggestive evidence for a role of USF1 in 
tumor suppression, one may anticipate that 
carcinogenesis will evolve from loss of USF1 
transactivation activity, either as a result of mutations 
in the USF1 gene or of posttranslational modification 
of USF1 protein. This has not been reported yet. 
Alternatively, tumor suppressor genes may lose 
responsivity to USF1 by mutations in the DNA binding 
element or by changes in local DNA methylation. This 
is exemplified by the observation of a classic Cowden 
syndrome patient with early onset breast cancer and 
reduced PTEN activity, which appears to be due to a 
specific germline mutation of an E-box element in the 
PTEN gene and loss of USF1 binding (Pezzolesi et al., 
2007). 
Familial combined hyperlipidemia 
(FCHL) 
Disease 
FCHL is the most common genetic form of 
hyperlipidemia and is associated with increased risk of 
premature cardiovascular disease. Affected persons 
characteristically show elevation of both cholesterol 
and triglycerides in the blood, which is due to increased 
VLDL and LDL levels. This is often accompanied by 
elevated apoB100 and low HDL levels, and a 
preponderance of small dense LDL particles 
(Naukkarinen et al., 2006). FCHL is genetically 
heterogeneous. One of the loci that is linked to FCHL 
is 1q21-q23. Pajukanta et al. (2004) showed that the 
dyslipidemia observed in FCHL is linked to the USF1 
gene. The disease is associated with a common 
haplotype of non-coding SNPs within the USF1 gene. 
Carriers of the risk allele show lack of insulin-induced 
increase of USF1 expression in skeletal muscle and fat 
tissue (Naukkarinen et al., 2009). As USF1 is involved 
in regulation of numerous genes of glucose and lipid 
metabolism (Corre and Galibert, 2005), non-responsive 
USF1 expression may lead to increased production and 
reduced metabolism of plasma lipids and lipoproteins. 
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